Your browser doesn't support javascript.
loading
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer.
Scagliotti, G V; Bondarenko, I; Blackhall, F; Barlesi, F; Hsia, T-C; Jassem, J; Milanowski, J; Popat, S; Sanchez-Torres, J M; Novello, S; Benner, R J; Green, S; Molpus, K; Soria, J-C; Shepherd, F A.
Afiliação
  • Scagliotti GV; Department of Oncology, University of Turin, Orbassano, Turin, Italy giorgio.scagliotti@unito.it.
  • Bondarenko I; Department of Oncology, Dnepropetrovsk Medical Academy, City Multiple-Discipline Clinical Hospital #4, Dnepropetrovsk, Ukraine.
  • Blackhall F; Manchester Cancer Research Centre Lung Group, Manchester University and Christie Hospital NHS Foundation Trust, Manchester, UK.
  • Barlesi F; Department of Multidisciplinary Oncology and Therapeutic Innovations, Aix Marseille University-Assistance Publique Hôpitaux de Marseille, Marseille, France.
  • Hsia TC; Department of Internal Medicine, China Medical University Hospital and China Medical University, Taichung, Taiwan.
  • Jassem J; Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk.
  • Milanowski J; Department of Pneumology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland.
  • Popat S; Lung Unit, Royal Marsden Hospital, London, UK.
  • Sanchez-Torres JM; Department of Medical Oncology, Hospital de la Princesa, Madrid, Spain.
  • Novello S; Department of Oncology, University of Turin, Orbassano, Turin, Italy.
  • Benner RJ; Department of Pfizer Oncology, Pfizer, Inc., Groton, USA.
  • Green S; Department of Pfizer Oncology, Pfizer, Inc., Groton, USA.
  • Molpus K; Department of Pfizer Oncology, Pfizer, Inc., Groton, USA.
  • Soria JC; Department of Clinical and Biological Sciences, Institut de Cancérologie Gustave Roussy and INSERM Unit 981, Villejuif, France.
  • Shepherd FA; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Ontario, Canada.
Ann Oncol ; 26(3): 497-504, 2015 Mar.
Article em En | MEDLINE | ID: mdl-25395283
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Pulmonar de Células não Pequenas / Cloridrato de Erlotinib / Neoplasias Pulmonares / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Pulmonar de Células não Pequenas / Cloridrato de Erlotinib / Neoplasias Pulmonares / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Itália